Imiquimod in lentigo maligna

Topical imiquimod before conservative excision of lentigo maligna (LM) may decrease surgical defect size, but should not be used as an alternative to surgery, researchers have said

Lentigo maligna: researchers studied use of topical imiquimod (Photograph: Dr Richard Turner)
Lentigo maligna: researchers studied use of topical imiquimod (Photograph: Dr Richard Turner)

Clinicians looked at 90 patients with 91 biopsy-confirmed LM who were randomised into two groups. One group (46 patients with 47 LM) received imiquimod 5% cream five days per week for three months, with 27 complete responses.
The other group of 44 patients with 44 LM received imiquimod and tazarotene 1% gel two days per week for three months, with 29 complete responses.

The patients were told to treat an area extending one inch beyond the outlined tumour margins and were monitored monthly for signs of inflammation and tumour regrowth. Afterwards, all patients had staged excision and frozen section analysis to confirm the negative margins.

The difference between the results of the two groups did not meet statistical significance (p =.17). There were no recurrences to date after a follow-up of 42 months. There was residual LM on staged excision in both groups, with 36% of lesions (15 of 42) in the imiquimod group and 22% of lesions (eight of 37) in the imiquimod plus tazarotene group.

The authors recommend topical imiquimod followed by conservative staged excision using 2mm margins.
Hyde MA, Hadley ML, Tristani-Firouzi P et al. Arch Dermatol 2012; 148(5): 592-6

Read these next

Clinical Review: melanoma

Clinical Review: melanoma

Sun protection campaigns are beginning to have an effect...

Common benign skin lesions in the elderly

Common benign skin lesions in the elderly

Benign skin lesions are often mistaken for more sinister...

Dermoscopy for diagnosing skin lesions

Dermoscopy for diagnosing skin lesions

GPs trained in dermoscopy are ideally placed to triage...

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases